Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
BCLI - Brainstorm Cell Therapeutics, Inc.
-0.28(-6.60%)8:59:54 PM 2/25/2021
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in Phase II for the treatment of multiple sclerosis, and preclinical trial for Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company has a partnership with Catalent for the manufacture of NurOwn, an autologous cellular therapy. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.


  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
Stock Statistics
PE Ratio
PEG Ratio
P/S (ttm)
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %18%
Held by Institutions %23%
1 Day Vol Adjusted Return-0.6
1 Month Vol Adjusted Return-3.7
3 Month Vol Adjusted Return-2.4
6 Month Vol Adjusted Return-9.0
20 Days SMA Price ZScore-2.0
50 Days SMA Price ZScore-1.6
12 -26 Days PPO-5.2
1 Month Average Short Volume Ratio46.5
1 Day Volume Change ZScore-0.3
1 Month Daily Vol10.9
Related Topics

Stock news

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI

    Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ: BCLI). Such investors are advised to contact Robert S. Willoughby at or 888-476-6529, ext. 9980.

    Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation

    Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or "the Company") (NASDAQ: BCLI). Investors who purchased Brainstorm securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site:

    BrainStorm to Present at SVB Leerink 10th Global Healthcare Conference

    BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that members of the management team will participate in the 10th Annual SVB Leerink Global Healthcare Conference.

    FDA Concludes BrainStorm's ALS Cell Therapy Lacks Substantial Data For Submission; Shares Drop

    The FDA's initial review concluded that current data from BrainStorm Cell Therapeutics Inc's (NASDAQ: BCLI) NurOwn Phase 3 trial in amyotrophic lateral sclerosis (ALS) does not sufficiently provide the threshold of substantial evidence to support the marketing application. Also, the FDA advised that this recommendation does not preclude Brainstorm from proceeding with a marketing application submission. "Brainstorm will first consult with principal investigators, ALS experts, expert statistician...

    BrainStorm Announces High-Level FDA Feedback on NurOwn® ALS Clinical Development Program

    BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase 3 clinical trial. The FDA concluded from their initial review that the current level of clinical data does not provide the threshold of substantial evid...

    BrainStorm Announces Feedback from FDA Type-C Meeting on Future NurOwn® Manufacturing Plan

    BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently concluded a Type C meeting with the U.S. Food and Drug Administration (FDA) to review specific aspects of the company's planned manufacturing modifications to support the development of a semi-automated commercial manufacturing process for NurOwn® (MSC-NTF cell). The meeting included a detailed review of the requirements for comparabi...

    We Think Brainstorm Cell Therapeutics (NASDAQ:BCLI) Needs To Drive Business Growth Carefully

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although

    BCLI: Waiting for Guidance from FDA on Potential Path Forward for NurOwn® in ALS…

    By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Update on NurOwn® in ALS BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) recently provided a corporate update that included information on NurOwn® and its potential regulatory path for amyotrophic lateral sclerosis (ALS). In November 2020, the company announced topline results from the Phase 3 clinical trial of

    Why BrainStorm Cell Therapeutics Blasted 27.7% Higher Today

    BrainStorm Cell Therapeutics' (NASDAQ: BCLI) stock price shot up by nearly 30% today, on the one-two punch of an encouraging metric or two in its quarterly results and an update about its most promising pipeline drug. For BrainStorm's Q4 of 2020, the clinical-stage biotech said that its net loss deepened to $31.8 billion, from the year-ago shortfall of nearly $23.3 million. What was likely a stronger tailwind for the stock on Thursday was BrainStorm's news about NurOwn, its treatment that orig...